Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Myrexis

Status and phase: Completed; Phase 1

Conditions: Brain Neoplasms

Treatments: Drug: MPC-6827

Study type: Interventional

Funder types: Industry

Identifiers

NCT00393965

MPC-6827-04-002

Details and patient eligibility

About

Phase 1, Multiple dose Study of MPC-6827 in Subjects with Refractory Brain Metastases.

Enrollment: 18 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Refractory Brain Metastases
• At least 1 measurable intracranial lesion as defined by RECIST
• ECOG less than or equal to 1
• Adequate hematology/organ function
• No baseline peripheral or central neuropathy above grade 1

Exclusion criteria

• Hypersensitivity to Cremophor EL
• Pregnant or Lactating
• Spinal Cord Compression
• Pre-existing dementia/cognitive disfunction
• Require Neupogen or Neulasta to Maintain Neutrophil Count
• Have Primary Brain Cancer
• Have History of Ischemic Heart Disease
• Have Diabetes

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)